The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics - PubMed
4 hours ago
- #gut-liver axis
- #precision medicine
- #MASLD
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition globally.
- The gut-liver axis is a central pathophysiological pathway in MASLD.
- Recent advances (2023-2025) highlight the role of the gut microbiome in MASLD.
- Causal links between gut dysbiosis and MASLD pathology are now established.
- Fecal microbiota transplantation (FMT) effectively prevents hepatic encephalopathy recurrence.
- Next-generation probiotics like Akkermansia muciniphila are in MASLD-specific trials.
- AI-driven diagnostic tools have achieved regulatory qualification from the European Medicines Agency.
- Host genetics, particularly PNPLA3 variants, influence MASLD risk and shape microbial communities.
- Precision strategies like bacteriophage therapy and defined probiotics are the future of MASLD management.